SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-044019
Filing Date
2023-12-07
Accepted
2023-12-07 16:15:28
Documents
13
Period of Report
2023-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36753
2 ex10-1.htm EX-10.1 124752
  Complete submission text file 0001493152-23-044019.txt   361242

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE qlgn-20231205.xsd EX-101.SCH 3009
4 XBRL LABEL FILE qlgn-20231205_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE qlgn-20231205_pre.xml EX-101.PRE 22355
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3323
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 231472558
SIC: 2834 Pharmaceutical Preparations